Recommended Treatment: Bisphosphonate Therapy
This 71-year-old woman should be started on bisphosphonate therapy (alendronate or zoledronic acid as first-line) based on her 20% major osteoporotic fracture risk, which meets the treatment threshold of ≥20% 10-year fracture risk. 1, 2
Risk Assessment Analysis
Your patient clearly meets treatment criteria through multiple pathways:
- FRAX score of 20% for major osteoporotic fracture exceeds the ≥20% treatment threshold 1, 3
- Bilateral hip T-scores of -2.2 place her in the osteopenic range approaching osteoporosis
- Age 71 years with hip T-score below -2.0 represents high fracture risk 1
- Hip fracture risk of 7% is at the threshold where screening trials showed benefit (mean 6.7-8.5% in positive trials) 1
The elevated C-telopeptide (485) indicates high bone turnover, supporting the need for antiresorptive therapy. Her vitamin D level of 38 ng/mL is adequate, calcium is normal, and PTH is not elevated—ruling out secondary causes that would require different management.
First-Line Treatment: Oral Bisphosphonates
Start with alendronate 70 mg weekly or risedronate 35 mg weekly as first-line therapy. 1, 2
The evidence strongly supports bisphosphonates:
- Vertebral fracture reduction: 49% relative risk reduction (18 fewer fractures per 1000 treated) 1
- Hip fracture reduction: 33% relative risk reduction (3 fewer fractures per 1000 treated) 1
- Generic availability and extensive safety data make this the standard initial choice 2, 4
Alternative if Oral Bisphosphonates Contraindicated
If she has esophageal disorders, cannot remain upright for 30 minutes, or has severe renal impairment (eGFR <35):
- Zoledronic acid 5 mg IV annually provides equivalent efficacy with once-yearly dosing 1
- Denosumab 60 mg subcutaneously every 6 months if bisphosphonates are contraindicated, though this requires indefinite continuation or structured exit strategy to prevent rebound vertebral fractures 3, 5
Critical Implementation Details
Bisphosphonate administration requirements:
- Take on empty stomach with 8 oz plain water
- Remain upright for 30-60 minutes after dosing
- No food, drink, or other medications for 30 minutes
- Ensure adequate calcium (1000-1200 mg daily) and vitamin D (800 IU daily minimum) 3
Her current vitamin D of 38 ng/mL is borderline—increase supplementation to 1000-2000 IU daily to maintain levels >40 ng/mL for optimal fracture prevention.
Monitoring Strategy
- Repeat DEXA in 1-2 years to assess treatment response 2
- Bone turnover markers (C-telopeptide) at 3-6 months should decrease by ≥30% if therapy is effective 6
- Continue treatment for 3-5 years initially, then reassess for drug holiday based on fracture risk and BMD response 4, 5
When to Consider Anabolic Therapy Instead
Do NOT use anabolic agents (teriparatide, romosozumab) as first-line in this patient. These are reserved for very high-risk patients with:
- Recent vertebral or hip fracture
- Multiple prior osteoporotic fractures
- T-score ≤-3.0
- Fracture while on bisphosphonate therapy 3, 5
Your patient does not meet these criteria. Anabolic-first sequences are for very high-risk patients, not those with osteopenia and no prior fractures.
Fall Prevention Integration
Given her age and fracture risk:
- Balance and resistance training twice weekly 7, 3
- Home safety assessment to remove fall hazards
- Vision and medication review (avoid sedating medications)
- Consider physical therapy referral for structured exercise program
Common Pitfalls to Avoid
Do not delay treatment waiting for BMD to worsen—her FRAX score alone justifies immediate therapy 1
Do not use denosumab as first-line unless bisphosphonates are contraindicated, because stopping denosumab requires complex transition therapy to prevent rebound fractures 5
Do not underdose vitamin D—her level of 38 ng/mL needs optimization to 40-50 ng/mL for fracture prevention 7
Do not forget calcium intake assessment—ensure 1200 mg total daily (diet plus supplement) 3